Trial reportPloS one2014
MicroRNA-10a is down-regulated by DNA methylation and functions as a tumor suppressor in gastric cancer cells.
Trial report in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 61 citations in OpenAlex.
- Serum level of miR-10-5p as a prognostic biomarker for acute myeloid leukemia.International journal of hematology · 2015Trial
- LncRNA MIR22HG and miR-10a-5p: Pioneering serum biomarkers for pancreatic cancer diagnosis and progression assessment.Non-coding RNA research · 2026Article
- Article
- Retraction: MicroRNA-10a Is Down-Regulated by DNA Methylation and Functions as a Tumor Suppressor in Gastric Cancer Cells.PloS one · 2023Article
- The emerging role of miR-10 family in gastric cancer.Cell cycle (Georgetown, Tex.) · 2021Review
- miR-7, miR-10a and miR-143 Expression May Predict Response to Bevacizumab Plus Chemotherapy in Patients with Metastatic Colorectal Cancer.Pharmacogenomics and personalized medicine · 2021Article
- Serum levels of microRNA-21 and microRNA-10a can predict long-term prognosis in laryngeal cancer patients: a multicenter study.Translational cancer research · 2020Article
- Methylation-Mediated Silencing of MicroRNA-497 Promotes Breast Cancer Progression Through Up-Regulation of Mucin1.Frontiers in oncology · 2020Article
- miR-10a-5p is increased in atopic dermatitis and has capacity to inhibit keratinocyte proliferation.Allergy · 2019Article
- microRNA arm-imbalance in part from complementary targets mediated decay promotes gastric cancer progression.Nature communications · 2019Article
- Clinical Features and MicroRNA Expression Patterns Between AML Patients With DNMT3A R882 and Frameshift Mutations.Frontiers in oncology · 2019Article
- Article
- The microRNA-10a/ID3/RUNX2 axis modulates the development of Ossification of Posterior Longitudinal Ligament.Scientific reports · 2018Article
- MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma.Journal of experimental & clinical cancer research : CR · 2018Article
- MicroRNA-10a/b are regulators of myeloid differentiation and acute myeloid leukemia.Oncology letters · 2018Article
- Involvement of methylation of MicroRNA-122, -125b and -106b in regulation of Cyclin G1, CAT-1 and STAT3 target genes in isoniazid-induced liver injury.BMC pharmacology & toxicology · 2018Article
- Epigenetics and MicroRNAs in Cancer.International journal of molecular sciences · 2018Review
- Transcriptomic profiling in human mesangial cells using patient-derived lupus autoantibodies identified miR-10a as a potential regulator of IL8.Scientific reports · 2017Article
- MicroRNA-10a suppresses breast cancer progression via PI3K/Akt/mTOR pathway.Oncology letters · 2017Article
- Regulation of spindle and kinetochore-associated protein 1 by antitumor miR-10a-5p in renal cell carcinoma.Cancer science · 2017Article
Corrections and comments
- Retraction · 2023-03-29Concerns/Issues about Authorship/Affiliation · Concerns/Issues about Image · Compromised Peer Review ·
- Retracted
Authors and funding
18 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicroRNAs act as posttranscriptional regulators of gene expression in many biological processes. Their deregulations occur commonly in gastric cancer (GC). Although DNA methylation constitutes an important mechanism for microRNA deregulation in cancer, this field largely remains unexplored. METHODOLOGY/PRINCIPAL
findingsTotal RNA was extracted from the tissues of 100 patients with GC and four gastric cancer cell lines. The expression levels of miR-10a were determined by real-time PCR with specific TaqMan probes. Moreover, a functional analysis of miR-10a in regulating cell proliferation, migration and invasion was performed. Subsequently, quantitative methylation-specific PCR (qMSP) was used to detect the DNA methylation status in the CpG islands upstream of miR-10a. In this study, we found that the expression of miR-10a in GC cells was lower than that in normal cells, which was due to the hypermethylation of the CpG islands upstream of miR-10a. We also validated the slightly lower expression of miR-10a in GC tissues than their adjacent non-neoplastic tissues in 100 GC patients and confirmed the hypermethylation of CpG islands upstream of miR-10a in some patients. Furthermore, re-introduction of miR-10a into GC cells was able to inhibit cell proliferation, migration and invasion. Bioinformatic and immunoblot analysis indicated that the tumor suppressor roles of miR-10a in GC cells were possibly through targeting HOXA1. CONCLUSIONS/SIGNIFICANCE: Our data indicate that miR-10a acts as a tumor suppressor in GC cells and is partially silenced by DNA hypermethylation in GC, suggesting that miR-10a may serve as a potential diagnostic or therapeutic target of GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.